YOUR CONDITION, EXPLAINED
Chronic Myelogenous Leukemia (CML) VA disability rating & claim guide
The VA rates Chronic Myelogenous Leukemia (CML) under diagnostic code 7719, in 38 CFR § 4.117 (hemic and lymphatic systems), and the schedule provides three evaluation levels for it: 100%, 60% and 30%.
Free · No account needed
Save your Chronic Myelogenous Leukemia (CML) guide
Email yourself this Chronic Myelogenous Leukemia (CML) guide so the rating criteria, evidence checklist, and preparation tips are easy to find later.
A CLEARER PATH FORWARD
Make sense of your next step.
01Understand the rating02Know what to gather03Plan your preparationTHE ESSENTIALS
How the VA rates Chronic Myelogenous Leukemia (CML)
DC 7719 is the only leukemia code in the schedule with a real ladder, and it grades treatment rather than disease. 100 percent requires a peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy. 60 percent is intermittent myelosuppressive therapy, or a tyrosine kinase inhibitor or interferon while not in apparent remission. 30 percent is apparent remission while still on continuous tyrosine kinase inhibitor therapy — which is where most veterans on modern CML treatment sit, and it is a compensable evaluation the schedule states outright rather than something that has to be argued.
DC 7719 states three evaluations, all written about treatment. 100 percent: requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment. 60 percent: requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission. 30 percent: in apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors. The axis is the therapy and, at the 60 and 30 percent tiers, whether the veteran is in apparent remission on it — the same drug class appears at both, and remission is what moves the evaluation down rather than the treatment stopping. Note (1): if the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703, which is the code covering every leukemia except this one and which pays 100 percent for active disease or a treatment phase. Note (2): a 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant, or during the period of treatment with chemotherapy including myelosuppressants; six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment, the appropriate disability rating shall be determined by mandatory VA examination; and any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of 38 CFR 3.105. So the total rating under Note (2) starts at admission rather than at discharge, and the six months that follow are counted from discharge or from the completion of chemotherapy, whichever applies. 38 CFR 4.31 supplies a 0 percent where the requirements for a compensable evaluation are not met, which under this code means no qualifying therapy at all.
- Diagnostic code
- 7719
- Rating schedule
- 38 CFR § 4.117
- Schedule levels
- 100%, 60% and 30%
How does the VA choose a rating level?
Which level applies is set by the criteria the evidence meets, not by the diagnosis. Where there is a question as to which of two evaluations applies, 38 CFR § 4.7 assigns the higher one if the disability picture more nearly approximates the criteria required for that rating.
This code prints no 0% row. Under 38 CFR § 4.31, a 0% evaluation is assigned where the requirements for a compensable evaluation are not met.
EXPLORE THE PERCENTAGES
Chronic Myelogenous Leukemia (CML) VA rating criteria (DC 7719)
Choose a percentage to see what that level means. Open the full comparison to read all the criteria in one place.
These are published rating criteria. Selecting a level does not predict your VA decision.
IN THE REGULATION’S OWN WORDS
What 38 CFR also says about Chronic Myelogenous Leukemia (CML)
The notes 38 CFR Part 4 prints with these criteria, quoted. They govern how the evaluation is made without being a rating level themselves.
- “Note (1): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703”DC 7719
- “Note (2): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant; or during the period of treatment with chemotherapy (including myelosuppressants). Six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105 of this chapter”DC 7719
BUILD YOUR EVIDENCE, ONE PIECE AT A TIME
Evidence for your Chronic Myelogenous Leukemia (CML) claim
A long list feels easier when you have a place to start. Use this checklist to see what you have and what still needs gathering.
Check off what you’ve gathered. Progress stays on this page until you leave or refresh.
THE EXAM FORM
Which DBQ is used for Chronic Myelogenous Leukemia (CML)?
VA's page says: “You can use these forms to submit medical evidence from your health care providers.”
Source: VA: Public Disability Benefits Questionnaires (DBQs), read September 18, 2026.
SMALL DETAILS. BETTER PREPARATION.
Preparing your Chronic Myelogenous Leukemia (CML) claim
Start with the practical tips, then explore the common oversights. You don’t need to work through everything at once.
Practical tips for your claim4 tips
- 01
Put the exact regimen and its continuity in the record. Continuous against intermittent, and targeted therapy against myelosuppressive therapy, are what the three tiers are made of.
- 02
Ask that apparent remission be stated explicitly one way or the other. It decides 60 against 30 percent for a veteran on the same medication.
- 03
Keep the transplant admission and discharge dates. Note (2) uses admission to start the total rating and discharge to start the six months.
- 04
If there has been leukemic transformation, say so. Note (1) evaluates the condition as leukemia under DC 7703 from that point.
C&P exam pitfalls to keep in mind4 tips
- 01
Tyrosine kinase inhibitor therapy recorded without saying whether the disease is in apparent remission. That is the whole difference between the 60 and the 30 percent criteria.
- 02
"Continuous" and "intermittent" used loosely. The 100 percent criterion asks for continuous myelosuppressive or immunosuppressive therapy and the 60 percent criterion for intermittent myelosuppressive therapy, so the distinction carries 40 points.
- 03
A transplant dated from discharge. Note (2) assigns the total evaluation as of the date of hospital admission.
- 04
Leukemic transformation not addressed. Note (1) moves the evaluation to DC 7703 when it occurs, which is a different code with a different criterion.
Common filing mistakes4 tips
- 01
Assuming remission ends the rating. The 30 percent criterion is written for a veteran in apparent remission who remains on continuous tyrosine kinase inhibitor therapy, so it is a stated compensable evaluation rather than a residual argument.
- 02
Filing CML under DC 7703. That code excludes chronic myelogenous leukemia in its own title; this is its code, and Note (1) is the only route between them.
- 03
Describing the drug without its class. The criteria name myelosuppressive therapy, immunosuppressive therapy, molecularly targeted therapy with tyrosine kinase inhibitors and interferon, and the tier follows the class.
- 04
Accepting a reduction after a transplant without the six months running. Note (2) counts them from hospital discharge, or from completion of chemotherapy, before the examination is even due.
When symptoms may first appear2 tips
- 01
The schedule states no course of onset for this code. Its tiers describe current therapy, so the evaluation follows the treatment being given rather than how or when the leukemia began.
- 02
The interval the regulation fixes is six months, counted from hospital discharge after a stem cell transplant or from completion of chemotherapy, to a mandatory VA examination — and the total rating it ends began at the date of admission rather than at discharge.
LET’S CLEAR A FEW THINGS UP
Common questions about Chronic Myelogenous Leukemia (CML)
Is Chronic Myelogenous Leukemia (CML) a VA-rated disability?
Yes. The VA rates Chronic Myelogenous Leukemia (CML) under VASRD diagnostic code 7719 (Hemic and Lymphatic Systems). DC 7719 is the only leukemia code in the schedule with a real ladder, and it grades treatment rather than disease. 100 percent requires a peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy. 60 percent is intermittent myelosuppressive therapy, or a tyrosine kinase inhibitor or interferon while not in apparent remission. 30 percent is apparent remission while still on continuous tyrosine kinase inhibitor therapy — which is where most veterans on modern CML treatment sit, and it is a compensable evaluation the schedule states outright rather than something that has to be argued.
What VA disability rating can I get for Chronic Myelogenous Leukemia (CML)?
Possible VA ratings for Chronic Myelogenous Leukemia (CML) are 100%, 60%, 30%, 0%. The 0% level comes from 38 CFR 4.31, which assigns it wherever no compensable level is met. Examples: 100%: Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment; 60%: Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission; 30%: In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors.
What evidence helps prove Chronic Myelogenous Leukemia (CML) for VA disability?
Strong evidence for a Chronic Myelogenous Leukemia (CML) claim includes: The current treatment regimen, named. Every tier of this code is a description of therapy — stem cell transplant, continuous or intermittent myelosuppressive therapy, tyrosine kinase inhibitors, interferon — so the medication record is the evaluation; A statement of whether the veteran is in apparent remission. It separates 60 percent from 30 percent on the same drug class, and it is the word the criteria use; For a transplant, the hospital admission and discharge dates. Note (2) assigns the 100 percent as of the date of admission and counts six months from discharge to the mandatory examination; Where chemotherapy was given, the date treatment was completed. Note (2) counts the same six months from completion in that case.
Which DBQ is used for Chronic Myelogenous Leukemia (CML)?
VA's Hematologic and Lymphatic Conditions, Including Leukemia Disability Benefits Questionnaire (DBQ) is on its public list of DBQs. VA's page says: "You can use these forms to submit medical evidence from your health care providers."
What mistakes should veterans avoid when claiming Chronic Myelogenous Leukemia (CML)?
Common pitfalls when filing for Chronic Myelogenous Leukemia (CML): Assuming remission ends the rating. The 30 percent criterion is written for a veteran in apparent remission who remains on continuous tyrosine kinase inhibitor therapy, so it is a stated compensable evaluation rather than a residual argument; Filing CML under DC 7703. That code excludes chronic myelogenous leukemia in its own title; this is its code, and Note (1) is the only route between them; Describing the drug without its class. The criteria name myelosuppressive therapy, immunosuppressive therapy, molecularly targeted therapy with tyrosine kinase inhibitors and interferon, and the tier follows the class; Accepting a reduction after a transplant without the six months running. Note (2) counts them from hospital discharge, or from completion of chemotherapy, before the examination is even due.
Can I get a VA rating for CML if I am in remission on a tyrosine kinase inhibitor?
Yes, and the schedule states it as a tier rather than leaving it to be argued. DC 7719's 30 percent criterion is "in apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors". The same drug class appears at 60 percent too - "molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission" - so what moves the evaluation between 60 and 30 is remission, not stopping the medication. That makes the one sentence worth getting into an examination report a statement of whether the veteran is in apparent remission.
When does the 100 percent for a stem cell transplant end?
Note (2) sets both ends of it. A 100 percent evaluation is assigned as of the date of hospital admission for the peripheral blood or bone marrow stem cell transplant, or during the period of treatment with chemotherapy including myelosuppressants. Six months following hospital discharge - or, for chemotherapy, six months after completion of treatment - the appropriate disability rating is determined by mandatory VA examination, and any reduction based on that or a subsequent examination is subject to 38 CFR 3.105. The date to watch is admission, not surgery or discharge: that is when the total evaluation begins.
Official sources
- 38 CFR § 4.117, Schedule of ratings, hemic and lymphatic systems (Diagnostic Code 7719)
- 38 CFR § 4.7, higher of two evaluations
- 38 CFR § 4.31, zero percent evaluations
Criteria in quotation marks are the regulation’s own words; everything else on this page is Vetrify’s summary of it. The eCFR text is authoritative. See how Vetrify derives its numbers.
How these figures are checked: our methodology and the open dataset.
VA Calc: Disability Pay
Combine your ratings & see monthly pay on your iPhone · Works offline